Featured Company News - Eli Lilly Achieves Positive Results for Second Phase-3 Study of Lasmiditan, an Acute Migraine Treatment
LONDON, UK / ACCESSWIRE / August 7, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Eli Lilly & Co. (NYSE: LLY) ("Eli Lilly"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=LLY. The Company announced on August 04, 2017, that lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, met its primary endpoint in SPARTAN, a second Phase-3 study. Lasmiditan also met the key secondary endpoint for SPARTAN across all the three doses, with a statistically significantly greater percentage of patients free of their most bothersome symptom compared against placebo at two hours post the first dose. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on LLY. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=LLY
The Tests
SPARTAN is a Phase-3 randomized, double-blind, placebo-controlled global trial evaluating the safety and efficacy of three doses of lasmiditan administered orally, against placebo. SAMURAI trial, on the other hand, is a Phase-3 randomized, double-blind, placebo-controlled US trial, to evaluate the safety and efficacy of two doses of lasmiditan compared with placebo for treatment of an acute migraine.
Under the SPARTAN study, at two hours following the first dose, a greater percentage of patients treated with lasmiditan were migraine pain-free compared to placebo. The results, according to the Company, were statistically significant across all the three studied doses (50 mg, 100 mg, and 200 mg).
The qualified patients had at least moderated migraine disability and had an average of more than five migraine attacks per month at baseline. SPARTAN also did not exclude patients with one or more cardiovascular risk factors, according to the Company. The primary end-point of the study was a comparison of the percentage of patients in the lasmiditan 200 mg, and placebo groups, who were migraine pain-free after two hours following the first dose, while the secondary endpoint was the comparison of the percentage of patients in the two groups, who were free of their most bothersome symptom.
Lasmiditan
Lasmiditan, according to the Company, has been designed to target receptors associated with migraine without the vasoconstrictor activity associated with some migraine therapies. The Company expects these results to be a significant step in the development of acute migraine treatments for patients served poorly by existing therapies, or those with cardiovascular disease and risk factors.
Lasmiditan was originally discovered at Eli Lilly and was out-licensed to CoLucid Pharmaceuticals in 2005. In March 2017, Eli Lilly completed the acquisition of CoLucid, including lasmiditan. Lasmiditan is a crucial addition to the Company's emerging pain management pipeline, which also includes galcanezumab, a potential medicine in Phase-3 clinical development for the prevention of a migraine and cluster headache. Additionally, Eli Lilly is collaborating with Pfizer, Inc., (NYSE:PFE) for the treatment of multiple pain indications, including osteoarthritis, lower back, and cancer pain.
The CoLucid Agreement
Currently, over 36 million people suffer from migraine in the United States. Lasmiditan, subject to being approved would be the unified solution to treat migraine through a novel mechanism of action without constriction. Initially, on January 18, 2017, Eli Lilly announced CoLucid for about $960 million. CoLucid had been developing lasmiditan, where it had completed the first of two pivotal Phase-3 trials. Eli Lilly stated then, that if the SPARTAN trial is positive, the submission of lasmiditan for US regulatory approval could occur in 2018.
Last Close Stock Review
On Friday, August 04, 2017, the stock closed the trading session at $82.31, slightly rising 0.46% from its previous closing price of $81.93. A total volume of 2.80 million shares have exchanged hands. Eli Lilly's stock price advanced 0.87% in the last one month and 6.58% in the past six months. Furthermore, since the start of the year, shares of the Company have surged 11.91%. The stock is trading at a PE ratio of 35.68 and has a dividend yield of 2.53%. The stock currently has a market cap of $90.20 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@protraderdaily.com
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily
